Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment

Junji Uchino, Koichi Takayama, Akiko Harada, Yosuke Kawakami, Hiroyuki Inoue, David T. Curiel, Yoichi Nakanishi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Treatment of advanced small-cell lung cancer (SCLC) remains one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and it also has an extremely poor prognosis. As a result, new therapeutic approaches are needed. Telomere maintenance to the regulation of replicative lifespan strongly implies that alterations in telomere biology play an important role during malignant transformation. Cancers that exhibit high levels of telomerase activity, such as all of the SCLC, were examined in a previous study. In this study, we turned the expression of human telomerase reverse transcriptase (hTERT) by tumors to a therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 (early region 1) is controlled by the hTERT promoter. This virus achieved good levels of viral replication in SCLC cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with a tropism modification of the virus to express the knob domain of Ad3 (serotype 3 adenovirus), and this improved infectivity for cancer cells. Conversely, the hTERT promoter has low activity in normal tissues, and the CRAd caused no damage to normal lung fibroblast cells. Since the telomerase activity is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that the use of hTERT promoter-based CRAds may be a potentially effective strategy for cancer treatment.

Original languageEnglish
Pages (from-to)737-748
Number of pages12
JournalCancer Gene Therapy
Volume12
Issue number9
DOIs
Publication statusPublished - Sep 1 2005

Fingerprint

Small Cell Lung Carcinoma
Adenoviridae
Neoplasms
Telomerase
Telomere
Viruses
Tropism
human TERT protein
Lung Neoplasms
Therapeutics
Fibroblasts
Maintenance
Medicine
Morbidity
Lung
Mortality

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Uchino, J., Takayama, K., Harada, A., Kawakami, Y., Inoue, H., Curiel, D. T., & Nakanishi, Y. (2005). Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Therapy, 12(9), 737-748. https://doi.org/10.1038/sj.cgt.7700838

Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. / Uchino, Junji; Takayama, Koichi; Harada, Akiko; Kawakami, Yosuke; Inoue, Hiroyuki; Curiel, David T.; Nakanishi, Yoichi.

In: Cancer Gene Therapy, Vol. 12, No. 9, 01.09.2005, p. 737-748.

Research output: Contribution to journalArticle

Uchino, J, Takayama, K, Harada, A, Kawakami, Y, Inoue, H, Curiel, DT & Nakanishi, Y 2005, 'Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment', Cancer Gene Therapy, vol. 12, no. 9, pp. 737-748. https://doi.org/10.1038/sj.cgt.7700838
Uchino, Junji ; Takayama, Koichi ; Harada, Akiko ; Kawakami, Yosuke ; Inoue, Hiroyuki ; Curiel, David T. ; Nakanishi, Yoichi. / Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. In: Cancer Gene Therapy. 2005 ; Vol. 12, No. 9. pp. 737-748.
@article{a38ad91054a241d8978837edd1bb5e48,
title = "Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment",
abstract = "Treatment of advanced small-cell lung cancer (SCLC) remains one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and it also has an extremely poor prognosis. As a result, new therapeutic approaches are needed. Telomere maintenance to the regulation of replicative lifespan strongly implies that alterations in telomere biology play an important role during malignant transformation. Cancers that exhibit high levels of telomerase activity, such as all of the SCLC, were examined in a previous study. In this study, we turned the expression of human telomerase reverse transcriptase (hTERT) by tumors to a therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 (early region 1) is controlled by the hTERT promoter. This virus achieved good levels of viral replication in SCLC cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with a tropism modification of the virus to express the knob domain of Ad3 (serotype 3 adenovirus), and this improved infectivity for cancer cells. Conversely, the hTERT promoter has low activity in normal tissues, and the CRAd caused no damage to normal lung fibroblast cells. Since the telomerase activity is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that the use of hTERT promoter-based CRAds may be a potentially effective strategy for cancer treatment.",
author = "Junji Uchino and Koichi Takayama and Akiko Harada and Yosuke Kawakami and Hiroyuki Inoue and Curiel, {David T.} and Yoichi Nakanishi",
year = "2005",
month = "9",
day = "1",
doi = "10.1038/sj.cgt.7700838",
language = "English",
volume = "12",
pages = "737--748",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment

AU - Uchino, Junji

AU - Takayama, Koichi

AU - Harada, Akiko

AU - Kawakami, Yosuke

AU - Inoue, Hiroyuki

AU - Curiel, David T.

AU - Nakanishi, Yoichi

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Treatment of advanced small-cell lung cancer (SCLC) remains one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and it also has an extremely poor prognosis. As a result, new therapeutic approaches are needed. Telomere maintenance to the regulation of replicative lifespan strongly implies that alterations in telomere biology play an important role during malignant transformation. Cancers that exhibit high levels of telomerase activity, such as all of the SCLC, were examined in a previous study. In this study, we turned the expression of human telomerase reverse transcriptase (hTERT) by tumors to a therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 (early region 1) is controlled by the hTERT promoter. This virus achieved good levels of viral replication in SCLC cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with a tropism modification of the virus to express the knob domain of Ad3 (serotype 3 adenovirus), and this improved infectivity for cancer cells. Conversely, the hTERT promoter has low activity in normal tissues, and the CRAd caused no damage to normal lung fibroblast cells. Since the telomerase activity is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that the use of hTERT promoter-based CRAds may be a potentially effective strategy for cancer treatment.

AB - Treatment of advanced small-cell lung cancer (SCLC) remains one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and it also has an extremely poor prognosis. As a result, new therapeutic approaches are needed. Telomere maintenance to the regulation of replicative lifespan strongly implies that alterations in telomere biology play an important role during malignant transformation. Cancers that exhibit high levels of telomerase activity, such as all of the SCLC, were examined in a previous study. In this study, we turned the expression of human telomerase reverse transcriptase (hTERT) by tumors to a therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 (early region 1) is controlled by the hTERT promoter. This virus achieved good levels of viral replication in SCLC cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with a tropism modification of the virus to express the knob domain of Ad3 (serotype 3 adenovirus), and this improved infectivity for cancer cells. Conversely, the hTERT promoter has low activity in normal tissues, and the CRAd caused no damage to normal lung fibroblast cells. Since the telomerase activity is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that the use of hTERT promoter-based CRAds may be a potentially effective strategy for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=23944496641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944496641&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700838

DO - 10.1038/sj.cgt.7700838

M3 - Article

C2 - 15861179

AN - SCOPUS:23944496641

VL - 12

SP - 737

EP - 748

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 9

ER -